Immunotherapy after Chemo-Radiation shows promise for rare throat cancer
NCT ID NCT04227509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding the immunotherapy drug pembrolizumab after standard chemoradiotherapy could help people with advanced nasopharyngeal carcinoma. Fifty-three patients received either pembrolizumab or a placebo every three weeks for up to a year. The main goal was to see if the drug improved the rate of patients who remained cancer-free after three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a new standard treatment to delay cancer progression in advanced nasopharyngeal carcinoma.
What could go wrong
This is a small, early-phase trial with only 53 participants, so results may not apply to everyone. The drug can cause immune-related side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Internal Medicine, Seoul National University Hospital
Seoul, 110-744, South Korea